These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 25762635

  • 1. Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.
    Wang L, Chen G, Chen K, Ren Y, Li H, Jiang X, Jia L, Fu S, Li Y, Liu X, Wang S, Yang J, Wu C.
    Oncotarget; 2015; 6(12):9740-55. PubMed ID: 25762635
    [Abstract] [Full Text] [Related]

  • 2. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer.
    Wang W, Zhao M, Cui L, Ren Y, Zhang J, Chen J, Jia L, Zhang J, Yang J, Chen G, Ashby CR, Wu C, Chen ZS, Wang L.
    Mol Cancer; 2020 Sep 02; 19(1):134. PubMed ID: 32878625
    [Abstract] [Full Text] [Related]

  • 3. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R.
    Clin Cancer Res; 2006 Jan 15; 12(2):634-42. PubMed ID: 16428510
    [Abstract] [Full Text] [Related]

  • 4. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J, Shivarudraiah P, Gavara G, Annamalai P, Natesan S, Sambasivam G, Sukumaran SK.
    Anticancer Res; 2015 Jan 15; 35(1):229-37. PubMed ID: 25550555
    [Abstract] [Full Text] [Related]

  • 5. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R.
    Cancer Res; 2004 Sep 15; 64(18):6626-34. PubMed ID: 15374977
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21WAF1/CIP1 expression.
    Tseng TH, Chien MH, Lin WL, Wen YC, Chow JM, Chen CK, Kuo TC, Lee WJ.
    Environ Toxicol; 2017 Feb 15; 32(2):434-444. PubMed ID: 26872304
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
    Li ZH, Zhang XB, Han XQ, Feng CR, Wang FS, Wang PG, Shen J, Shi YK.
    Oncol Rep; 2013 Jul 15; 30(1):499-505. PubMed ID: 23624828
    [Abstract] [Full Text] [Related]

  • 8. hRAD9 functions as a tumor suppressor by inducing p21-dependent senescence and suppressing epithelial-mesenchymal transition through inhibition of Slug transcription.
    Wen FC, Chang TW, Tseng YL, Lee JC, Chang MC.
    Carcinogenesis; 2014 Jul 15; 35(7):1481-90. PubMed ID: 24403312
    [Abstract] [Full Text] [Related]

  • 9. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW, Lien JC, Kuo SC, Huang TF.
    Carcinogenesis; 2012 May 15; 33(5):1022-30. PubMed ID: 22436611
    [Abstract] [Full Text] [Related]

  • 10. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC, Heo JH, Jeon JY, Choi HJ, Jo AR, Kim SW, Kwon HJ, Hong SJ, Han KS.
    BMC Cancer; 2015 Jan 23; 15():19. PubMed ID: 25613585
    [Abstract] [Full Text] [Related]

  • 11. PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis.
    Peng F, Li Q, Sun JY, Luo Y, Chen M, Bao Y.
    Int J Oncol; 2018 Mar 23; 52(3):945-954. PubMed ID: 29393396
    [Abstract] [Full Text] [Related]

  • 12. Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion.
    Kim NH, Kim SN, Kim YK.
    Biochem Biophys Res Commun; 2011 Jan 28; 404(4):915-21. PubMed ID: 21184735
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1/Cip1 and p19INK4d upregulation in hepatocellular carcinoma.
    Zhou H, Cai Y, Liu D, Li M, Sha Y, Zhang W, Wang K, Gong J, Tang N, Huang A, Xia J.
    Cell Prolif; 2018 Jun 28; 51(3):e12447. PubMed ID: 29484736
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid.
    Chia JS, Du JL, Hsu WB, Sun A, Chiang CP, Wang WB.
    BMC Cancer; 2010 Apr 30; 10():175. PubMed ID: 20429953
    [Abstract] [Full Text] [Related]

  • 15. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
    Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R.
    Mol Cancer Ther; 2007 Jan 30; 6(1):70-81. PubMed ID: 17237267
    [Abstract] [Full Text] [Related]

  • 16. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
    Lin YC, Lin YC, Shih JY, Huang WJ, Chao SW, Chang YL, Chen CC.
    Clin Cancer Res; 2015 Jan 15; 21(2):428-38. PubMed ID: 25593344
    [Abstract] [Full Text] [Related]

  • 17. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
    Chen J, Li N, Liu B, Ling J, Yang W, Pang X, Li T.
    Life Sci; 2020 May 01; 248():117469. PubMed ID: 32109485
    [Abstract] [Full Text] [Related]

  • 18. Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy.
    Zhu S, Zhu W, Zhao K, Yu J, Lu W, Zhou R, Fan S, Kong W, Yang F, Shan P.
    Cell Commun Signal; 2024 Jul 15; 22(1):361. PubMed ID: 39010083
    [Abstract] [Full Text] [Related]

  • 19. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
    Yang Z, Shen M, Tang M, Zhang W, Cui X, Zhang Z, Pei H, Li Y, Hu M, Bai P, Chen L.
    Eur J Med Chem; 2019 Sep 15; 178():116-130. PubMed ID: 31177073
    [Abstract] [Full Text] [Related]

  • 20. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM.
    Breast Cancer Res; 2012 May 21; 14(3):R79. PubMed ID: 22613095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.